The second anti-CGRP mechanism following Emgality is expected to be approved in Korea.

According to related industries, Teva Handok is in discussions for domestic approval of Ajovy(Fremanezumab), a migraine treatment targeting Calcitonin gene-related peptide (CGRP). Approval is possible within the first half of the year.

The effectiveness of Ajovy in preventing migraine headaches was evaluated through two phase 3 placebo-controlled clinical studies in migraine patients who had difficulty in daily life, and proved the efficacy of reducing the number of migraine incidence days compared to the placebo group.

As a result, Ajovy competes with Emgality (Galcanezumab) in the reim